<div><div></div><div><span><p><strong><span>Corvus Pharmaceuticals reported Phase 1 soquelitinib data showing durable, drug-free remissions and favorable safety.</span></strong></p><p><strong><span>Key Highlights:</span></strong></p><ul><li><span>Phase 1 trial (72 patients) showed dose-dependent efficacy and additional benefit with longer treatment.</span></li><li><span>Cohort 3 (200 mg BID): 50% EASI-75, 8% EASI-90, 25% IGA 0/1; responses durable through 90-day follow-up.</span></li><li><span>Cohort 4 (200 mg BID, 8 weeks): 75% EASI-75, 25% EASI-90, 33% IGA 0/1; no rebound or rescue meds in 30-day follow-up.</span></li><li><span>Safety profile comparable to placebo: AEs in 41.7% of soquelitinib and 41.7% of placebo patients; all Grade 1-2, no SAEs.</span></li><li><span>Biomarker data support ITK inhibition: reduced Th2/Th17 markers, increased persistent Tregs, and JAK‑STAT pathway modulation.</span></li></ul><p><span>Original SEC Filing: </span>Corvus Pharmaceuticals, Inc. [ CRVS ] - 8-K - May. 14, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

CRVS

IBBQ

<p>Corvus Pharmaceuticals presented Phase 1 data for soquelitinib, demonstrating durable drug-free remissions and a favorable safety profile. The trial involved 72 patients, showing dose-dependent efficacy with significant results in Cohorts 3 and 4. Cohort 3 achieved 50% EASI-75 and 25% IGA 0/1, while Cohort 4 reached 75% EASI-75 and 33% IGA 0/1, with no rebound effects noted. Adverse events were comparable to placebo, all Grade 1-2. Biomarker data indicated effective ITK inhibition, supporting the drug's potential.</p>

TradingView

Corvus Pharma

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Health Care Select Sector SPDR

Direxion S&P Biotech Bull 3X

VG Health

VanEck Biotech ETF

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

iShares US Pharma

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety